Literature DB >> 973984

Serum concentrations and bioavailability of rifampicin and isoniazid in combination.

J C Garnham, T Taylor, P Turner, L F Chasseaud.   

Abstract

The bioavailability of rifampicin and isoniazid from formulations containing these drugs in combination has been compared to that from formulations containing either drug alone. No formulation-related differences in either rates or extent of bioavailability were found after administration of each formulation. Mean peak serum concentrations of rifampicin (8.2-11.7 mug/ml) occurring 2 to 4 h after doses of 600 mg, and isoniazid (3.6-4.8 mug/ml) occurring 0.5 to 1 h after doses of 300 mg, were similar to those reported in the literature.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 973984      PMCID: PMC1428926          DOI: 10.1111/j.1365-2125.1976.tb00644.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Inactive prednisone tablets U.S.P. XVI.

Authors:  F A CAMPAGNA; G CURETON; R A MIRIGIAN; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

2.  Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite.

Authors:  G Boman; P Lundgren; G Stjernström
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

3.  Serum concentration of rifampin after oral administration.

Authors:  S Virtanen; E Tala
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

4.  Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

Authors:  G Boman
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Diphenylhydantoin intoxication. A complication of isoniazid therapy.

Authors:  H Kutt; R Brennan; H Dehejia; K Verebely
Journal:  Am Rev Respir Dis       Date:  1970-03

6.  How reliable are enteric-coated aspirin preparations?

Authors:  R L Clark; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1965 Sep-Oct       Impact factor: 6.875

7.  Genetic variations in the acetylation of isoniazid and other drugs.

Authors:  D A Evans
Journal:  Ann N Y Acad Sci       Date:  1968-07-31       Impact factor: 5.691

8.  Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses.

Authors:  J G Wagner
Journal:  J Pharm Sci       Date:  1967-05       Impact factor: 3.534

9.  Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes.

Authors:  A M Jezequel; F Orlandi; L T Tenconi
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

10.  EFFECT OF DOSAGE FORM PROPERTIES ON THERAPEUTIC EFFICACY OF TOLBUTAMIDE TABLETS.

Authors:  G LEVY
Journal:  Can Med Assoc J       Date:  1964-04-18       Impact factor: 8.262

View more
  9 in total

1.  Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

2.  A Hyaluronic Acid Hydrogel Loaded with Gentamicin and Vancomycin Successfully Eradicates Chronic Methicillin-Resistant Staphylococcus aureus Orthopedic Infection in a Sheep Model.

Authors:  Willemijn Boot; Tanja Schmid; Matteo D'Este; Olivier Guillaume; Andrew Foster; Laurent Decosterd; Robert G Richards; David Eglin; Stephan Zeiter; Thomas F Moriarty
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Radiometric macrophage culture assay for rapid evaluation of antileprosy activity of rifampin.

Authors:  A Mittal; P S Seshadri; H K Prasad; M Sathish; I Nath
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

5.  Rifampin affects polymorphonuclear leukocyte interactions with bacterial and synthetic chemotaxins but not interactions with serum-derived chemotaxins.

Authors:  G D Gray; C W Smith; J C Hollers; D E Chenoweth; V D Fiegel; R D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

7.  Rifampin Pharmacokinetics and Safety in Preterm and Term Infants.

Authors:  P Brian Smith; C Michael Cotten; Mark L Hudak; Janice E Sullivan; Brenda B Poindexter; Michael Cohen-Wolkowiez; Felix Boakye-Agyeman; Andrew Lewandowski; Ravinder Anand; Daniel K Benjamin; Matthew M Laughon
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.938

8.  Real time monitoring of Staphylococcus aureus biofilm sensitivity towards antibiotics with isothermal microcalorimetry.

Authors:  Andi Rofian Sultan; Mehri Tavakol; Nicole A Lemmens-den Toom; Peter D Croughs; Nelianne J Verkaik; Annelies Verbon; Willem J B van Wamel
Journal:  PLoS One       Date:  2022-02-16       Impact factor: 3.240

9.  Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of B. burgdorferi.

Authors:  Richard I Horowitz; Krithika Murali; Gauri Gaur; Phyllis R Freeman; Eva Sapi
Journal:  BMC Res Notes       Date:  2020-09-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.